SEQUENTIAL THERAPY WITH BRENTUXIMAB VEDOTIN IN NEWLY DIAGNOSED PATIENTS WITH SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA

被引：0
|
作者：
Fanale, M. [1 ]
Advani, R. [2 ]
Bartlett, N. L. [3 ]
Davies, A. [4 ]
Illidge, T. [5 ]
Kennedy, D. A. [6 ]
Shustov, A. R. [7 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
[3] Washington Univ, Sch Med, St Louis, MO USA
[4] Southampton Univ Hosp, Southampton, Hants, England
[5] Univ Manchester, Christie Hosp NHS, Manchester, Lancs, England
[6] Seattle Genet Inc, Clin Affairs, Bothell, WA USA
[7] Univ Washington, Med Ctr, Div Hematol, Seattle, WA 98195 USA
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：348 / 348
页数：1
相关论文
共 50 条
  • [21] Brentuximab Vedotin: A Review of Its Use in Patients with Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma Following Previous Treatment Failure
    Karly P. Garnock-Jones
    Drugs, 2013, 73 : 371 - 381
  • [22] Brentuximab Vedotin: A New Age in the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
    Minich, Stephanie S.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (03) : 377 - 383
  • [23] Brentuximab Vedotin: A Review of Its Use in Patients with Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma Following Previous Treatment Failure
    Garnock-Jones, Karly P.
    DRUGS, 2013, 73 (04) : 371 - 381
  • [24] Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin
    Sahin, Mustafa
    Miskioglu, Mine
    Inanir, Isil
    Akar, Hikmet
    Nese, Nalan
    Temiz, Peyker
    Aydogdu, Ismet
    TURKISH JOURNAL OF HEMATOLOGY, 2021, 38 (01) : 85 - 87
  • [25] Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma
    Heidegger, Simon
    Beer, Ambros J.
    Geissinger, Eva
    Rosenwald, Andreas
    Peschel, Christian
    Ringshausen, Ingo
    Keller, Ulrich
    ONCOTARGETS AND THERAPY, 2014, 7 : 1123 - 1127
  • [26] Brentuximab Vedotin and Ifosfamide, Carboplatin, and Etoposide (ICE) Combination Therapy for Refractory Anaplastic Large Cell Lymphoma
    Inoue, Shotaro
    Tamura, Akihiro
    Noguchi, Jun
    Nakamura, Sayaka
    Kozaki, Aiko
    Saito, Atsuro
    Ishida, Toshiaki
    Mori, Takeshi
    Hasegawa, Daiichiro
    Kosaka, Yoshiyuki
    PEDIATRIC BLOOD & CANCER, 2020, 67
  • [27] Cost-effectiveness of brentuximab vedotin for relapsed or refractory systemic anaplastic large-cell lymphoma in China
    Liu, Jia
    Zheng, Lei
    Chuang, Ling-Hsiang
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 99 - 107
  • [28] Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study
    Fukuhara, Noriko
    Yamamoto, Go
    Tsujimura, Hideki
    Chou, Takaaki
    Shibayama, Hirohiko
    Yanai, Tomoko
    Shibuya, Kazunori
    Izutsu, Koji
    LEUKEMIA & LYMPHOMA, 2020, 61 (01) : 176 - 180
  • [29] Phase I Trial of Brentuximab Vedotin for Children with Recurrent or Refractory Hodgkin's Lymphoma or Systemic Anaplastic Large Cell Lymphoma
    Sekimizu, Masahiro
    Koga, Yuki
    Iguchi, Akihiro
    Mori, Tetsuya
    Asada, Ryuta
    Kada, Akiko
    Saito, Akiko
    Horibe, Keizo
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S11 - S12
  • [30] Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin
    Chihara, Dai
    Wong, Shannon
    Feldman, Tatyana
    Fanale, Michelle A.
    Sanchez, Larysa
    Connors, Joseph M.
    Savage, Kerry J.
    Oki, Yasuhiro
    HEMATOLOGICAL ONCOLOGY, 2019, 37 (01) : 35 - 38
12345